bioAffinity Technologies, Inc. Warrant - BIAFW STOCK NEWS

bioAffinity Technologies to present corporate update and hold meetings with investors at H.C. Wainwright conference

bioAffinity Technologies reports financial results for Q2 2023 and provides business update

bioAffinity Technologies, Inc. will present research findings at the University of Massachusetts RNA Therapeutics Symposium. The study shows that deprivation of vitamin B12 does not play a role in the selective cytotoxicity of cancer cells after silencing specific genes. The company aims to develop targeted therapeutics for multiple cancers.

bioAffinity Technologies, Inc. has reported financial results for Q1 2023. Highlights include the appointment of a new CFO, progress in the branding and marketing strategy for CyPath® Lung, and positive clinical validation study results. The company plans to expand the commercial launch of CyPath® Lung and conduct a pivotal clinical trial. Revenue for Q1 2023 was $1,000, compared to no revenue in the prior-year period. Net loss for Q1 2023 was $1.5 million. Cash and cash equivalents as of March 31, 2023, were $9.8 million.

bioAffinity Technologies (Nasdaq: BIAF; BIAFW) will present at the Cleveland Clinic’s Advances in Early Lung Cancer Detection symposium on April 27, 2023. Dr. Vivienne I. Rebel will discuss advancements in the company’s product, CyPath^® Lung, a noninvasive test for early-stage lung cancer detection utilizing flow cytometry and artificial intelligence. The symposium aims to improve lung cancer diagnosis, particularly during its most treatable early stages. This marks bioAffinity's fourth invitation to present, underscoring its ongoing engagement in pioneering cancer detection technologies. CyPath^® Lung demonstrates high sensitivity and specificity and is marketed through Precision Pathology Services. The company’s subsidiary, OncoSelect^® Therapeutics, is also developing targeted cancer treatments.

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) will ring the Nasdaq closing bell to celebrate its 2022 IPO. President and CEO Maria Zannes expressed gratitude for the opportunity, highlighting milestones leading to the launch of its noninvasive cancer detection product, CyPath® Lung. This test is aimed at early-stage lung cancer detection, enhancing treatment effectiveness and patient outcomes. The closing bell ceremony will be streamed live on various platforms, showcasing bioAffinity's commitment to innovation in early cancer diagnostics.